ProQinase
ProQinase is a Germany-based preclinical drug discovery CRO operating under Reaction Biology, providing kinase profiling, epigenetic, cell-based, biophysical, and in vivo pharmacology services to pharmaceutical, biotech, and academic clients across US and EU facilities.
- Company typePrivate
- Founded2001
- HeadquartersFreiburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What ProQinase does
ProQinase is a contract research organization (CRO) specializing in preclinical drug discovery services with a primary focus on kinase profiling and epigenetic target screening. Founded in 2001 and headquartered in Freiburg, Germany, the company operates under the Reaction Biology legal entity with facilities in the European Union and the United States. Its service portfolio spans biochemical assays (kinase panels, methyltransferase, HDAC, HAT, demethylase, GPCR, ion channel, phosphatase), cell-based assays (ProLiFiler cancer cell panel, 3D tumor spheroids, immune checkpoint, CAR-T), biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology (xenograft, orthotopic, PK/PD), safety/toxicology, GMP bioassays, and custom assay development. Proprietary platforms include LinkLight (protein-protein interaction analysis), ProLiFiler (cancer cell panel screening), and SubQperior (tumor models), supported by a library of hundreds of validated proteins and over 1,000 cell lines.
The company serves pharmaceutical companies, biotechnology firms, and academic research institutions, with named relationships including Boehringer-Ingelheim, Perha Pharmaceuticals, ManRos Therapeutics, the University of North Carolina at Chapel Hill, and Ludwig-Maximilian's University of Munich. Revenue is generated primarily through project-based contract research services and the sale of recombinant kinase proteins and assay reagents, with pricing structured on a quote-per-project basis typical of enterprise CRO engagements. Recent product expansion covers emerging modalities including Antibody Drug Conjugates, RAS drug discovery, Targeted Protein Degradation, and EGFR programs, alongside an immuno-oncology service line and entry into the Chinese market via a localized website. Leadership is provided by CEO Sebastian Dempe and founder Christoph Schächtele, who has been involved since the company's inception.
ProQinase firmographics
Firmographics- Name
- ProQinase
- Legal name
- Reaction Biology
- Website
- https://proqinase.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ProQinase is a Germany-based preclinical drug discovery CRO operating under Reaction Biology, providing kinase profiling, epigenetic, cell-based, biophysical, and in vivo pharmacology services to pharmaceutical, biotech, and academic clients across US and EU facilities.
- Ownership category
- akta.pro rank
ProQinase industry classification
Industry- Product category
- Preclinical Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), DMPK / ADME & Bioanalysis (HLAGAFAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where ProQinase is headquartered
LocationHeadquarters
- HQ city
- Freiburg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
ProQinase business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: CRO services providing preclinical drug discovery including biochemical assays, cell-based assays, biophysical assays, safety & toxicology, in vivo pharmacology, and custom assay development for pharmaceutical, biotech, and academic clients
- Recombinant Protein Products: Sale of kinase proteins, epigenetic proteins, and related assay reagents including active protein kinases, lipid kinases, methyltransferase proteins, deacetylase proteins, and assay kits
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CRO project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
ProQinase product offering
Product offeringCore offering
ProQinase, operating as the kinase services brand of Reaction Biology, is a contract research organization (CRO) providing preclinical drug discovery services. Core offerings include kinase panel screening, biochemical and cell-based assays, biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology, immuno-oncology platforms, recombinant kinase proteins, and safety/toxicology testing for pharmaceutical, biotech, and academic clients.
Product overview
ProQinase (now part of Reaction Biology) offers an integrated drug discovery service portfolio. The core offerings include kinase panel screening services and recombinant kinase products (Active Protein Kinases, Active Lipid Kinases), supplemented by epigenetic assay services (Methyltransferase, Demethylase, HDAC, HAT, Reader Domain assays). The platform includes discovery tools (KinaseFinder, Kinase SubstrateFinder, Kinase Mapper, MoA Finder, Biomarker Analysis Tool) for target identification and compound profiling. Additional services span biophysical assays (SPR, MST, ITC, TSA), cell-based assays (ProLiFiler Cancer Cell Panel, 3D Tumor Spheroid), in vivo pharmacology models, immuno-oncology platforms (CAR-T), GMP bioassays, safety/toxicology screening, and custom drug discovery services. The product line also includes assay kits (BromoMELT Assay Kit) and reagent products. The company operates from strategically located facilities in the US and EU with over 1,000 cell lines and hundreds of validated protein targets.
Differentiator
Problem solved
Functional benefit
Products and services
- Kinase Panel Screening Comprehensive screening of kinases across the kinome to identify target engagement and selectivity profiles for pharmaceutical, biotech, and academic clients.
- Kinase Assay Services Individual kinase assay services providing quantitative measurement of kinase activity and inhibition for drug discovery clients.
- Epigenetic Assay Services Biochemical assays for profiling methyltransferase, demethylase, histone acetyltransferase (HAT), histone deacetylase (HDAC), sirtuin, and reader domain activity for epigenetic drug discovery.
- Biophysical Assay Services Biophysical assays including Surface Plasmon Resonance (SPR), Thermal Shift Assay (TSA), Microscale Thermophoresis (MST), and Isothermal Titration Calorimetry (ITC) for measuring molecular interactions and binding kinetics.
- ProLiFiler Cancer Cell Panel Screening Proprietary cancer cell line panel screening service for phenotypic profiling of compound efficacy across a panel of cancer cell lines.
- 3D Tumor Spheroid Assay Three-dimensional cell culture assay using tumor spheroids for physiologically relevant drug efficacy testing in oncology drug discovery.
- CAR-T Cell Therapy Platform Platform for evaluating CAR-T cell therapeutic candidates and immune responses in immuno-oncology drug discovery.
- In Vivo Pharmacology Preclinical in vivo efficacy models including xenograft tumor models, PK/PD studies, and translational pharmacology for drug discovery programs.
- GMP Bioassays Regulatory-compliant bioanalytical testing and quality control services for bioprocessing and biotherapeutic manufacturing.
- Safety & Toxicology Services Comprehensive safety profiling including in vitro safety screening, cardiac safety assessment, cytochrome P450 assays, and GLP toxicology for drug development programs.
- Custom Drug Discovery Services Customized kinase and epigenetic drug discovery services tailored to specific client research needs, including custom assay development and cell line generation.
- Active Protein Kinases Recombinant active protein kinases sold as standalone reagents for use in biochemical screening and profiling assays.
- Active Lipid Kinases Recombinant lipid kinases sold as standalone reagents for lipid kinase inhibitor screening and research.
- BromoMELT Assay Kit Assay kit for measuring bromodomain binding and ligand-induced thermal stability, sold as a standalone reagent product.
Quantifiable outcome
- Therapies developed using company services have received regulatory approval from FDA and other global regulatory agencies
Companies that use ProQinase
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
ProQinase technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ProQinase partnerships and signals
Strategic signalScale indicators4 records
Recent moves1 record
Expansion highlights5 records
ProQinase competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: Eurofins Scientific is the parent of Eurofins Discovery and DiscoverX, offering a broad CRO footprint across pharma discovery, in vivo, safety, and bioanalytical services. It competes with ProQinase through multiple subsidiaries, particularly in kinase profiling, safety assessment, and biomarker assays.
- Charles River Laboratories: Charles River is a large preclinical CRO with end-to-end discovery, safety assessment, and in vivo pharmacology capabilities. Its Early Discovery and Safety Assessment segments overlap directly with ProQinase's biochemical, cell-based, in vivo, and GLP toxicology offerings, often competing for the same enterprise pharma programs at greater scale.
- Labcorp Drug Development: Labcorp (including its Covance legacy) offers preclinical and clinical CRO services spanning discovery biology, safety assessment, and bioanalytical/PK work. It competes with ProQinase in cell-based profiling, in vivo pharmacology, biomarker, and safety/toxicology service lines, typically at much larger scale.
- Reaction Biology Corporation: Reaction Biology is the parent platform that operates ProQinase as a sub-brand. Reaction Biology's broader discovery-services catalog (biochemical, cell-based, biophysical, in vivo, safety) overlaps directly with ProQinase's offerings, while ProQinase contributes kinase and epigenetic specialty depth within the same corporate family.
- Thermo Fisher Scientific (PPD): Thermo Fisher's PPD CRO segment provides preclinical and clinical research services including discovery biology, bioanalytical, and safety assessment. It overlaps with ProQinase in biochemical and cell-based assay services and competes for global pharma R&D outsourcing budgets at significantly greater scale.
Direct peers
- Promega Corporation: Promega supplies kinase assay reagents, luminescent and fluorescent biochemical kits, and cell-based profiling tools that overlap with ProQinase's kinase and biochemical assay services. Both serve pharma and academic customers needing validated, reproducible enzyme and cell-based assay infrastructure.
- DiscoverX (Eurofins): DiscoverX, now part of Eurofins, provides cell-based and biochemical assay platforms (e.g., PathHunter, KINOMEscan) for kinase, GPCR, and other drug target screening. It competes head-to-head with ProQinase's kinase panel screening, KinaseFinder tools, and cell-based profiling services.
- Eurofins Discovery: Eurofins Discovery is a leading specialty CRO offering in vitro pharmacology, kinase profiling, cell-based assays, and in vivo services — directly mirroring ProQinase's preclinical drug discovery menu. Both compete for the same pharma and biotech discovery-program contracts across kinase, biophysical, and cell-based assay modalities.
- Selvita: Selvita is a contract research organization providing integrated drug discovery services including biochemical and cell-based assays, in vitro ADME, in vivo pharmacology, and medicinal chemistry. Its discovery-service portfolio is a strong direct comparator to ProQinase's preclinical offering.
- Carna Biosciences: Carna Biosciences is a kinase-focused Japanese CRO and reagent provider with biochemical kinase profiling, cell-based kinase assays, and a kinase inhibitor screening platform. Its product-and-service mix is the closest direct comparator to ProQinase's kinase specialty franchise.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ProQinase social profiles
Digital presenceProQinase financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProQinase leadership team
Management profileNumber of profiles
Profiles2 records
ProQinase funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProQinase M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProQinase
What does ProQinase do?
ProQinase, operating as the kinase services brand of Reaction Biology, is a contract research organization (CRO) providing preclinical drug discovery services. Core offerings include kinase panel screening, biochemical and cell-based assays, biophysical assays (SPR, MST, ITC, TSA), in vivo pharmacology, immuno-oncology platforms, recombinant kinase proteins, and safety/toxicology testing for pharmaceutical, biotech, and academic clients.
When was ProQinase founded?
ProQinase was founded in 2001. It employs 11 to 50 people.
Where is ProQinase based?
ProQinase is headquartered in Freiburg, Germany, in the Europe region.
How does ProQinase make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are recombinant Protein Products.
Who are ProQinase's main competitors?
Broad incumbents on record are Eurofins Scientific, Charles River Laboratories, Labcorp Drug Development, Reaction Biology Corporation and Thermo Fisher Scientific (PPD). Direct peers are Promega Corporation, DiscoverX (Eurofins), Eurofins Discovery, Selvita and Carna Biosciences.
Does ProQinase have an API?
No public API is recorded for ProQinase.
What industry is ProQinase in?
ProQinase's product category is Preclinical Drug Discovery Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 541714 and its SIC code is 8731.